Sun Pharmaceutical Industries has received US health regulator’s approval for generic docetaxel injection, used in treating cancer, in the American market. The company’s subsidiary - Sun Pharma Advanced Research Company - has received abbreviated new drug approval from US Food and Drug Administration for Docefrez in strength of 20 mg/vial and 80 mg/vial. The company’s product is indicated for metastatic breast cancer, lung cancer and hormone refractory metastatic prostate cancer. This product could potentially give the company over $50 million over a year.
